A Phase 2 interventional study of EPI-743 in Pearson Syndrome, sponsored by Edison Pharmaceuticals Inc. Terminated at 4 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Edison Pharmaceuticals Inc (part of PTC Therapeutics) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in VLCAD deficiency with a site in United States — 1 open to participants now, 3 under way, none of them phase 3. VLCAD deficiency · United States.
Among the 12 studies in VLCAD deficiency with a site in United States, this one is one of 3 that started in 2014, is one of 4 in phase 2, and was the 4th registered.
26 studies on the registry are indexed under VLCAD deficiency; 6 are open to participants now.
Browse VLCAD deficiency studies →1 of the 12 studies in VLCAD deficiency with a site in United States is open now. Recruiting first, the newest first:
Children's National Research Institute · Sites in United States
Ages 7–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 VLCAD deficiency studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 13 across 15 interventional studies indexed under VLCAD deficiency.
Median enrollment 31 across the 6 interventional studies, 30 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Edison Pharmaceuticals Inc, one of the names counted as PTC Therapeutics. Under that name alone:
Edison Pharmaceuticals Inc is the lead sponsor of 7 studies on the registry; none are open to participants now.
PTC Therapeutics has 1 study filed under VLCAD deficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in VLCAD deficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in VLCAD deficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Treatment of Pediatric Subjects with Pearson syndrome
If effective, treatment with EPI-743 should result in a significant reduction in occurrence of sepsis, metabolic crisis, hepatic failure and transfusion dependence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg/kg EPI-743 to be administered three times per day for 1 year
Drug: EPI-743
EPI-743 is the quinone oxidation product of alpha-tocotrienol
Also known as: Vincerinone (TM)
Occurence of episodes of sepsis, metabolic crisis or hepatic faillure
Time frame: 1 year
Transfusion avoidance
Time frame: 1 year
Hematologic function
Time frame: 1 year
Neuromuscular function
Neuromuscular function as assessed by Gross Motor Function Measure
Time frame: 1 year
Disease severity
Disease severity as assessed by Newcastle Pediatric Mitochondrial Disease Scale
Time frame: 1 year
Renal function
Time frame: 1 year
Hepatic function
Time frame: 1 year
Weight gain
Time frame: 1 year
Hospitalizations
Time frame: 1 year
Pancreatic function
Pancreatic function as assessed by insulin requirement and hemoglobin A1c
Time frame: 1 year
Mortality
Time frame: 1 year
Number of Dose Limiting SAEs
Any adverse event greater than or equal to grade 3 that is deemed related to treatment with EPI-743 and not related to underlying disease
Time frame: 1 year
Ran from Aug 2014 to primary completion in Nov 2015, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha-tocotrienol quinone